SUMMIT THERAPEUTICS INC (SMMT) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 45% based on the firm’s underlying fundamentals and the stock ...

In recent trading, shares of Summit Therapeutics Inc (Symbol: SMMT) have crossed above the average analyst 12-month target price of $35.57, changing hands for $36.70/share. When a stock reaches ...

Summit Therapeutics PLC (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, will visit the Nasdaq MarketSite ...

The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 44.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

Shares of lung cancer-focused biotech Summit Therapeutics (NASDAQ: SMMT) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Summit Therapeutics (SMMT) one of those stocks right now ...

Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning. Summit has been a tremendous winner over the past ...

Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) are both up-and-coming biotechs with no sales revenue, plenty of cash in the bank, big catalysts on the horizon, and ...

Summit Therapeutics SMMT is a clinical-stage biopharmaceutical company focused on the development and marketing of medicinal therapies to treat oncology indications with serious unmet needs.

Summit Therapeutics PLC (SMMT) shares soared 17.4% in the last trading session to close at $8.04. The move was backed by solid volume with far more shares changing hands than in a normal session ...

Is Summit Therapeutics (SMMT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.